Healthcare - The Plimsoll Portfolio Analysis.

The financial health and commercial success of the Top 2000 companies in the UK Healthcare industry has been analysed in the Plimsoll Portfolio Analysis - Healthcare. The latest 2007 edition includes a 4 year analysis and a FREE “Profit Plan” for each company, showing how profitability could be improved over the next 12 months.

Complete with acquisition recommendations and accurate, up to date industry intelligence, there is no better method of analysing the UK Healthcare industry. The latest analysis highlights a staggering £2.4 billion of profit being wasted in the UK Healthcare industry every year. This is due to blatant underperformance and a failure by company leaders to focus on the bottom line.

The following conclusions about the industry can be reached within minutes of opening the analysis:

	£2.4bn profit is lost every year.
	50 companies are 'ripe' for acquisition.
	A third of companies are loss making.
	383 companies enjoyed over 20% growth
	27 companies did not grow at all last year
	50 companies are aggressively attacking the market share of others

The exclusive analysis examines 1000 companies in the UK Healthcare industry individually using the Plimsoll Model. By confining each company in the UK industry to a single page, the latest Plimsoll Portfolio Analysis allows for comparative analysis in an instant. Features include:

	A FREE "Profit Plan" has been added to each company's analysis.
	2000 companies individually analysed using the Plimsoll Model.
	EVERY company rated as either a Winner, Loser, Chancer or Sleeper.
	The Best Acquisition Prospects named and analysed.
	Over 100 pages of comprehensive industry analysis
	In depth analysis of each competitors strategy.
	Exceptional companies in the industry identified.

The Plimsoll Portfolio Analysis - Healthcare is available now in either Paper or the brand new Electronic version. Order on line today and receive FREE couriered delivery within 48 hours. Please browse the links for more information about our unique and unrivalled analysis.